Trial reportJournal of psychopharmacology (Oxford, England)2009
Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial.
Trial report in Journal of psychopharmacology (Oxford, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.Nature genetics · 2020Pooled it
- Efficacy of Olibra: a 12-week randomized controlled trial and a review of earlier studies.Journal of diabetes science and technology · 2012Trial
- A Study of Adverse Drug Reactions to Antiepileptic Drugs in Pediatric Epileptic Patients From North India.Cureus · 2025Article
- Unraveling the nutritional challenges in epilepsy: Risks, deficiencies, and management strategies: A systematic review.World journal of experimental medicine · 2025Article
- Advancing ex vivo functional whole-organ prostate gland model for regeneration and drug screening.Scientific reports · 2025Article
- Treatment of oxidative damage caused by valproic acid in tongue tissue with ethanolic Moringa oleifera leaves extract and prediction of potential bioactive molecules with molecular docking.Journal of molecular histology · 2024Article
- Rauvolfia vomitoria phenol extract relieves pentylenetetrazol-induced seizures in Swiss mice and protects some temporal lobe structures.Acta epileptologica · 2024Article
- Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy.Frontiers in pharmacology · 2024Article
- Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor γ transactivation.Frontiers in endocrinology · 2023Article
- Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences.Current neuropharmacology · 2019Review
- A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.The pharmacogenomics journal · 2017Article
- Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus?Frontiers in endocrinology · 2017Article
- White Matter Hyperintensities on Brain Magnetic Resonance Imaging in People with Epilepsy: A Hospital-Based Study.CNS neuroscience & therapeutics · 2016Article
- Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease.PloS one · 2015Article
- Article
- Comparative Effect of Divided Doses of Adult Solid and Liquid Oral Formulations of Antiepileptic Drugs in the Management of Pediatric Epilepsy.Journal of pharmacology & pharmacotherapeuticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The objective of this study was to identify mechanisms through which valproic acid (VPA) causes weight gain. Healthy participants (N = 52) were randomized to VPA or placebo in a double-blind study. Energy intake (EI) was measured in the laboratory at lunch and dinner, and physical activity (PA) was measured with accelerometry. Glucose levels and hormones [Peptide YY(3-36), glucagon-like peptide-1 (GLP-1), leptin, ghrelin, insulin] that regulate EI were measured. Assessments occurred at baseline and week 3. Change from baseline was evaluated with mixed models (alpha = 0.05). Weight significantly increased in the VPA group (+0.49 kg), but not the placebo group. The VPA group increased fast food fats cravings and decreased glucose levels compared with placebo. Change in weight, EI and PA did not differ by group. Within group analyses indicated that the VPA group increased PA, hunger, binge eating, depression and GLP-1. VPA-associated weight gain is not likely due to changes in PA or the gut hormones studied. Although EI did not increase when measured after 3 weeks of treatment, VPA decreased glucose levels and increased motivation to eat; hence, EI might have increased in the short-term. Research testing VPA on short-term (1 week) EI, metabolism, and substrate partitioning is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.